The FDA and Safe Use of Long-Acting Beta-Agonists in the Treatment of Asthma

Authors:
  • GPGerald Dal Pan
    Gerald Dal Pan

Abstract
For over a decade, the Food and Drug Administration (FDA) and the medical community have discussed how to safely use long-acting beta-agonists (LABAs) — drugs designed to provide bronchodilation for 12 hours or longer through stimulation of the β2-adrenergic receptor.1 Even before U.S. approval of the first LABA, there was concern about a paradoxical increase in serious asthma exacerbations in some patients treated with these drugs. The Serevent nationwide surveillance (SNS) study suggested an increased risk of asthma-related death in patients treated with salmeterol as compared with albuterol, a short-acting beta-agonist (SABA). Shortly after approving salmeterol in 1994, the FDA began to receive reports of serious asthma exacerbations and deaths in patients treated with the drug. To further evaluate these reports, the manufacturer conducted the Salmeterol Multicenter Asthma Research Trial (SMART), in which, over the course of 28 weeks, there were eight more asthma-related deaths per 10,000 patients among patients treated with salmeterol than among those given placebo (95% confidence interval, 3 to 13).1 Smaller studies of formoterol showed an excess of serious asthma exacerbations, some necessitating intubation.1 Although the absolute risk observed is small, it is not inconsequential, given the number of patients with asthma currently receiving these drugs. There is particular concern about the risk among children. Public discussions at FDA advisory committee meetings in 2005, 2007, and 2008 (summarized at www.fda.gov), as well as discussions in the Journal,2-4 reflect the varied interpretations of these data and their implications for the safe use of LABAs.

This publication has 3 references indexed in Scilit: